WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206475
CAS#: 1434048-34-6 (free base)
Description: Fenebrutinib, also known as GDC-0853, is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.
MedKoo Cat#: 206475
Name: Fenebrutinib free base
CAS#: 1434048-34-6 (free base)
Chemical Formula: C37H44N8O4
Exact Mass: 664.3486
Molecular Weight: 664.811
Elemental Analysis: C, 66.85; H, 6.67; N, 16.86; O, 9.63
Fenebrutinib (GDC-0853), purity > 98%, is in stock. The same day shipping out after order is received.
Related CAS #: 1434048-34-6 (free base) 2128304-54-9 (HCl) 2128304-53-8 (mesylate) 2128304-55-0 (sulfate)
Synonym: GDC-0853; GDC 0853; GDC0853; RG-7845; RG7845; RG 7845; Fenebrutinib; Fenebrutinib free base;
IUPAC/Chemical Name: (S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one
InChi Key: WNEODWDFDXWOLU-QHCPKHFHSA-N
InChi Code: InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1
SMILES Code: O=C1C(N2CCN1C3=NC=CC(C(C=C4NC5=NC=C(N6[C@@H](C)CN(C7COC7)CC6)C=C5)=CN(C)C4=O)=C3CO)=CC8=C2CC(C)(C)C8
The following data is based on the product molecular weight 664.811 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Heteroarylpyridone and azapyridone compounds as inhibitors of BTK activity and their preparation
By Crawford, James John; Ortwine, Daniel Fred; Wei, Binqing; Young, Wendy B.
From PCT Int. Appl. (2013), WO 2013067274 A1 20130510.
Note: Structure was from https://newdrugapprovals.org/2016/03/ ( visited on 4/7/2016)